Melanoma associated with the use of melanotan-II
- PMID: 24355990
- DOI: 10.1159/000356389
Melanoma associated with the use of melanotan-II
Abstract
Background: Unlicensed use of melanotan-II (MT-II) to promote skin pigmentation has become prevalent amongst young people attending fitness centres. We present a case where the melanocyte stimulation of MT-II in combination with the use of sun tanning beds coincided with cutaneous melanoma.
Observation: A 20-year-old woman with Fitzpatrick skin type II was referred to a dermatology clinic. Clinical examination revealed a suspicious black melanocytic lesion in her left gluteal region. Furthermore, her skin was universally intensely pigmented. The melanocytic lesion was excised, and histology confirmed the diagnosis of melanoma. Three months prior to the excision the patient had conducted a 3- to 4-week course of self-injections with MT-II, intending an augmentation of sunbed tanning.
Conclusions and relevance: This observation brings attention to the potential risks related to the use of the cyclic α-melanocyte-stimulating hormone analogue MT-II. There are several hazardous aspects of the possible widespread use of MT-II. As the drug is unlicensed and incompletely tested, the extent and types of adverse effects are unknown. Clinicians are advised to be aware of the problem, and counsel their at-risk patients regarding the potential hazards related to the use of MT-II.
© 2013 S. Karger AG, Basel.
Similar articles
-
Atypical melanocytic naevi following melanotan injection.Ir Med J. 2013 May;106(5):148-9. Ir Med J. 2013. PMID: 23914578
-
Melanotan-associated melanoma in situ.Australas J Dermatol. 2012 Nov;53(4):301-2. doi: 10.1111/j.1440-0960.2012.00915.x. Epub 2012 Jun 22. Australas J Dermatol. 2012. PMID: 22724573
-
An in-depth case examination of an exotic dancer's experience of melanotan.Int J Drug Policy. 2014 May;25(3):444-50. doi: 10.1016/j.drugpo.2013.10.008. Epub 2013 Nov 1. Int J Drug Policy. 2014. PMID: 24280586
-
Update on tanning: More risks, fewer benefits.J Am Acad Dermatol. 2014 Mar;70(3):562-8. doi: 10.1016/j.jaad.2013.11.004. Epub 2013 Dec 31. J Am Acad Dermatol. 2014. PMID: 24388421 Review.
-
Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.Int J Dermatol. 2017 Oct;56(10):975-980. doi: 10.1111/ijd.13585. Epub 2017 Mar 7. Int J Dermatol. 2017. PMID: 28266027 Review.
Cited by 2 articles
-
The melanocortin pathway and control of appetite-progress and therapeutic implications.J Endocrinol. 2019 Apr 1;241(1):R1-R33. doi: 10.1530/JOE-18-0596. J Endocrinol. 2019. PMID: 30812013 Free PMC article. Review.
-
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.Clin Pharmacokinet. 2017 Aug;56(8):815-823. doi: 10.1007/s40262-016-0501-5. Clin Pharmacokinet. 2017. PMID: 28063031 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials